Abstract: Disclosed is a display panel includes a base substrate, a display structure layer, and a touch structure layer. The base substrate includes a display region, a second bezel region located on a side of the display region and a first bezel region located on remaining sides of the display region. The display structure layer includes at least one first crack detection line and a plurality of data leading-out lines. The touch structure layer includes at least one second crack detection line The first crack detection line and the second crack detection line are connected in series in the second bezel region through a plurality of detection connection lines. An orthographic projection of at least one detection connection line on the base substrate is overlapped with an orthographic projection of at least one data leading-out line on the base substrate.

Abstract: Provided are an anti-Claudin 18.2 antigen-binding fragment or antibody, and the use thereof. CDR3 of a heavy chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 3. CDR3 of a light chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 6. The provided antigen-binding fragment and anti-Claudin 18.2 antibody can specifically bind to a variety of sources of Claudin 18.2 proteins, have no binding effect on other proteins, and have a high specificity. In addition, a chimeric antigen receptor and a CAR-T cell prepared by means of the antibody have obvious cytotoxicity on cells stably expressing the Claudin 18.2 protein.

Abstract: Methods and devices for encrypting Network Configuration Protocol (NETCONF) datastore in communication networks are disclosed. One of the methods is performed by a device using NETCONF. The method comprises enabling a function for NETCONF Datastore Security (DS-SEC). The method further comprises publishing a first indication indicating that the device supports the NETCONF DS-SEC function.

Abstract: A nucleic acid ligand and a conjugate thereof, and a preparation method therefor and the use thereof. Specifically, provided is a ligand having the structure as represented by formula (I). The provided ligand achieves a good expression inhibition effect by means of the conjugation with a nucleic acid.

Abstract: An apparatus, method, and computer-readable storage medium for magnetron sputtering for thin film deposition. The apparatus may include a chamber for thin film deposition, configured to house a target configured to be held by a target holder, and a pedestal configured to support a substrate, and arranged opposite to the target; a magnetron configured to generate a magnetic field around a surface of the target, for electron confinement, and to facilitate ignition and maintenance of plasma; a main power supply, configured to apply power to the target to form an electrical field, the electrical and magnetic fields can convert at least a part of working gas into the plasma, and the electrical field can direct a part of ions in the plasma toward the target; and a resistance measurement meter in electrically connection with each of an electrical ground point and the target, and configured to measure a resistance therebetween.

Abstract: Provided are an anti-B7H3 antibody and the use thereof. A variable region of the antibody comprises amino acid sequences as shown in SEQ ID NOs: 25-39. The anti-B7H3 antibodies 26B6, 6F7, 2B8, and 23H1 have a significant binding capability to B7H3, can not only bind to purified or free B7H3 protein, but also can bind to B7H3 protein on a cell surface; and after humanized modification, the affinity between the antibody and B7H3 is further improved, and the antibody has important application prospects in clinical diagnosis and/or treatment of B7H3-positive tumors.

Abstract: Methods for constructing an ADR prediction model for elderly patients, a prediction system, and/or a storage medium are disclosed. The method includes constructing ADR trigger entries for elderly patients; based on the ADR trigger entries for elderly patients, combining evidence-based evaluation results to construct a dataset of risk factors related to ADRs in elderly patients; completing the annotation of risk factors and ADR discrimination for the dataset related to ADRs in elderly patients; using the annotated dataset information to train a machine learning model, so as to obtain an ADR risk prediction model for elderly patients. A prediction system utilizing the ADR prediction model for elderly patients is constructed.

Abstract: Provided is a chimeric antigen receptor targeting CLL1 and an application thereof. The chimeric antigen receptor targeting CLL1 comprises an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain; the antigen binding domain is an anti-CLL1 antibody. The present application uses an anti-CLL1 antibody as the antigen binding domain to construct a chimeric antigen receptor molecule, the chimeric antigen receptor targeting CLL1 has specific targeting effect on CLL1 positive tumor cells, and immune cells expressing chimeric antigen receptor targeting CLL1 have a significant killing effect in vitro and in vivo, and secrete a large amount of cytokine IFN-? after co-cultured with CLL1 positive tumor cells, which has a specific clearance effect on CLL1 positive tumor cells.

Abstract: The present invention relates to LPA-targeting siRNA and a conjugate, and specifically relates to LPA-targeting siRNA, a siRNA conjugate, a composition, and a pharmaceutical use thereof. The present invention also relates to a pharmaceutical composition, a cell or a kit comprising the siRNA, and a method for the siRNA and the siRNA conjugate for treating and/or preventing related disorders suffered by a subject.

Abstract: An apparatus, method, and computer-readable storage medium for magnetron sputtering for thin film deposition. The apparatus may include a chamber for thin film deposition, configured to house a target configured to be held by a target holder, and a pedestal configured to support a substrate, and arranged opposite to the target; a magnetron configured to generate a magnetic field around a surface of the target, for electron confinement, and to facilitate ignition and maintenance of plasma; a main power supply, configured to apply power to the target to form an electrical field, the electrical and magnetic fields can convert at least a part of working gas into the plasma, and the electrical field can direct a part of ions in the plasma toward the target; and a resistance measurement meter in electrically connection with each of an electrical ground point and the target, and configured to measure a resistance therebetween.

Abstract: An alkali metal monohydrogen cyanurate compound of the chemical formula AM(HC3N3O3)·nH2O (specifically such as KLi(HC3N3O3)·2H2O, RbLi(HC3N3O3)·2H2O, RbNa(HC3N3O3)·2H2O) and a nonlinear optical crystal thereof are related to optoelectronic functional materials. Measured using a powder frequency doubling test method, and the powder frequency doubling effect of the nonlinear optical crystal is about 2-3 times that of KH2PO4 (KDP). The ultraviolet absorption edge of the nonlinear optical crystal is shorter than 250 nm. The nonlinear optical crystal can achieve the harmonic generator of double, triple, or quadruple frequency for Nd: YAG (?=1.064 ?m). Moreover, the nonlinear optical crystal is of a single crystalline structure, is colorless and transparent, and does not deliquesce in air.

Abstract: Methods and systems for data management optimization are disclosed. The methods involve retrieving at least one of data querying instructions or data generating paths, and constructing knowledge graphs to visualize data structure within the data objects. Data objects are matched to determine similarities among the knowledge graphs. Cost functions determined by the similarities generate costs to evaluate aspects of the data objects, which are then ranked to inform data processing workflows within the data management system. This disclosure improves data handling efficiency and operational performance.

Abstract: Methods for constructing an ADR prediction model for elderly patients, a prediction system, and/or a storage medium are disclosed. The method includes constructing ADR trigger entries for elderly patients; based on the ADR trigger entries for elderly patients, combining evidence-based evaluation results to construct a dataset of risk factors related to ADRs in elderly patients; completing the annotation of risk factors and ADR discrimination for the dataset related to ADRs in elderly patients; using the annotated dataset information to train a machine learning model, so as to obtain an ADR risk prediction model for elderly patients. A prediction system utilizing the ADR prediction model for elderly patients is constructed.

Abstract: Provided is an anti-CLL1 antibody and an application thereof. The variable region of the anti-CLL1 antibody includes the CDRs of SEQ ID NO: 1 to 6, SEQ ID NO: 5, and SEQ ID NO: 7 to 11 or SEQ ID NO: 12 to 17. The anti-CLL1 antibody of the present application has significant binding ability to both free and cell surface CLL1. After humanization, the affinity of the antibody to CLL1 is further improved, and it has important application prospect in the clinical diagnosis and/or treatment of tumors.

Abstract: The present disclosure relates to the field of biomedicine, in particular, to a CD300LD inhibitor and use thereof in the preparation of tumor immunotherapy products. In the present disclosure, the CD300LD inhibitor regulates the migration and function of PMN-MDSC cells by modulating S100A8/A9 in its downstream signaling pathway, and plays an important role in the establishment of the tumor microenvironment. The polypeptide isolated by the present disclosure is used as a CD300LD inhibitor, and CD300LD-ECD protein can inhibit CD300LD by competitive binding, thus inhibiting tumor development. When tumor-bearing mice are treated with this peptide, the development of tumors can be significantly inhibited. In addition, CD300LD-ECD has a significant anti-tumor synergistic effect with PD1 antibody.

Abstract: This invention belongs to the field of preparation of macromolecule sample of various volumes, pertaining to a detergent-mixed dry hydrogel particle and a method of using the particle to mass concentrate the macromolecule liquid sample or to enhance specific activity of the protein liquid sample. After thorough suspension and hydration in a detergent solution, the hydrogel particle is separated from the excess of the detergent solution and dried into the detergent-mixed dry hydrogel particle; upon contacting the macromolecule liquid sample in certain ratio with the dry particle having a pore size of its cross-linked network smaller than the macromolecule to allow absorption and swelling of the hydrogel particle, filter centrifugation or filter conical rotating drum centrifugation is exercised to remove the hydrogel particle whose surface is deprived of water and to collect the concentrate filtrate of the macromolecule mass or the protein sample with enhanced specific activity.